Perri Silvia, Greer Catherine E, Thudium Kent, Doe Barbara, Legg Harold, Liu Hong, Romero Raul E, Tang Zequn, Bin Qian, Dubensky Thomas W, Vajdy Michael, Otten Gillis R, Polo John M
Vaccine Research, Chiron Corporation, Emeryville, California 94608, USA.
J Virol. 2003 Oct;77(19):10394-403. doi: 10.1128/jvi.77.19.10394-10403.2003.
Alphavirus replicon particle-based vaccine vectors derived from Sindbis virus (SIN), Semliki Forest virus, and Venezuelan equine encephalitis virus (VEE) have been shown to induce robust antigen-specific cellular, humoral, and mucosal immune responses in many animal models of infectious disease and cancer. However, since little is known about the relative potencies among these different vectors, we compared the immunogenicity of replicon particle vectors derived from two very different parental alphaviruses, VEE and SIN, expressing a human immunodeficiency virus type 1 p55(Gag) antigen. Moreover, to explore the potential benefits of combining elements from different alphaviruses, we generated replicon particle chimeras of SIN and VEE. Two distinct strategies were used to produce particles with VEE-p55(gag) replicon RNA packaged within SIN envelope glycoproteins and SIN-p55(gag) replicon RNA within VEE envelope glycoproteins. Each replicon particle configuration induced Gag-specific CD8(+) T-cell responses in murine models when administered alone or after priming with DNA. However, Gag-specific responses varied dramatically, with the strongest responses to this particular antigen correlating with the VEE replicon RNA, irrespective of the source of envelope glycoproteins. Comparing the replicons with respect to heterologous gene expression levels and sensitivity to alpha/beta interferon in cultured cells indicated that each might contribute to potency differences. This work shows that combining desirable elements from VEE and SIN into a replicon particle chimera may be a valuable approach toward the goal of developing vaccine vectors with optimal in vivo potency, ease of production, and safety.
源自辛德毕斯病毒(SIN)、 Semliki森林病毒和委内瑞拉马脑炎病毒(VEE)的基于甲病毒复制子颗粒的疫苗载体,已被证明在许多传染病和癌症动物模型中可诱导强烈的抗原特异性细胞免疫、体液免疫和黏膜免疫反应。然而,由于对这些不同载体之间的相对效力了解甚少,我们比较了源自两种截然不同的亲本甲病毒VEE和SIN的复制子颗粒载体的免疫原性,它们表达1型人类免疫缺陷病毒p55(Gag)抗原。此外,为了探索组合不同甲病毒元件的潜在益处,我们构建了SIN和VEE的复制子颗粒嵌合体。采用两种不同策略生产颗粒,一种是将VEE-p55(gag)复制子RNA包装在SIN包膜糖蛋白内,另一种是将SIN-p55(gag)复制子RNA包装在VEE包膜糖蛋白内。每种复制子颗粒构型在单独给药或经DNA预免疫后,均可在小鼠模型中诱导Gag特异性CD8(+)T细胞反应。然而,Gag特异性反应差异很大,对该特定抗原的最强反应与VEE复制子RNA相关,而与包膜糖蛋白来源无关。比较复制子在培养细胞中的异源基因表达水平和对α/β干扰素的敏感性表明,每种因素都可能导致效力差异。这项工作表明,将VEE和SIN的理想元件组合到复制子颗粒嵌合体中,可能是开发具有最佳体内效力、易于生产和安全性的疫苗载体的一种有价值的方法。